RxDoctor Payments DataLook up a doctor →

Caroline Flake

Acute Care · Charleston, SCNPI 1346720596

Payments from drug & device makers

$8,453in general payments, 2019–2025

Across 331 payments — averaging $25.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$723
  • Merck$630
  • Daiichi Sankyo Inc.$494
  • AstraZeneca$461
  • Bristol Myers Squibb$387
  • Novartis$358
  • plus $5K from 52 others

What the payments were for

  • Food & beverage$8,35399%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,453 in reported general payments places this provider in the 95th percentile of 339 acute care providers in South Carolina.

See all acute care providers in South Carolina

Medicare billing

Part B allowed, 2024
$84,480
Medicare patients
301
Services billed
1,483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PomalystPomalidomide31$603,294
RevlimidLenalidomide30$598,844
XospataGilteritinib Fumarate15$368,121
VenclextaVenetoclax42$241,923
DopteletAvatrombopag Maleate12$173,790
CalquenceAcalabrutinib Maleate11$165,029
InqoviDecitabine/Cedazuridine12$99,531
EliquisApixaban68$61,592
Posaconazole22$55,389
Abiraterone Acetate13$25,728
Fondaparinux Sodium11$10,044
Acyclovir104$1,187
Letrozole37$650
Ondansetron OdtOndansetron31$554
Gabapentin25$339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Pomalyst$211$603,29431 claims
Bristol Myers SquibbRevlimid$387$598,84430 claims
Astellas Pharma US IncXospata$211$368,12115 claims
AbbVieVenclexta$184$241,92342 claims
Dova PharmaceuticalsDoptelet$125$173,79012 claims
AstraZenecaCalquence$461$165,02911 claims
Taiho Oncology, Inc.Inqovi$108$99,53112 claims
PfizerEliquis$289$61,59268 claims
Lilly USA, LLCOlanzapine$246$33223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 339 acute care providers in South Carolina.

Other acute care in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →